1:CAR-T cells

4 trials

Sponsors

The Affiliated Hospital of Xuzhou Medical College, The Affiliated Hospital of Xuzhou Medical University

Conditions

B-cell hematologic malignanciesMultiple Myeloma

Phase 2

A clinical study of chimeric antigen receptor T-cell immunotherapy in the treatment of CD19+ B-cell hematologic malignancies

RecruitingChiCTR-OIC-16008291

The Affiliated Hospital of Xuzhou Medical CollegeB-cell hematologic malignancies

Start: 2016-04-01Updated: 2017-04-18

An open single center single arm clinical study of t fully human anti-CD19 CAR-T therapy for CD19+ B-cell hematologic malignancies

RecruitingChiCTR-OIC-17011271

The Affiliated Hospital of Xuzhou Medical UniversityB-cell hematologic malignancies

Start: 2017-05-01Updated: 2017-05-09

Clinical study on the safety and efficacy of allogeneic hematopoietic stem cell transplantation combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies

RecruitingChiCTR-OIC-17012374

The Affiliated Hospital of Xuzhou Medical UniversityB-cell hematologic malignancies

Start: 2017-08-01Updated: 2017-08-21

Unknown Phase

An open single center single arm clinical study of through infusion of anti-BCMA CAR-T and anti-CD19 CAR-T therapy for relapsed and refractory multiply myeloma

RecruitingChiCTR-OIC-17011272

The Affiliated Hospital of Xuzhou Medical UniversityMultiple Myeloma

Start: 2017-05-01Updated: 2021-06-07

Related Papers

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma

Frontiers in Immunology2022-10-1823 citations

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

Frontiers in Immunology2022-04-2714 citations

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.

2019-08-01247 citations